#non-Hodgkin's lymphoma

CAR-T Therapy: Lifeline to A Cure?

The personalized CAR-T therapy prolonged cancer remission compared with standard therapy.

Researchers are examining opportunities for immune-modulating approaches to improve outcomes and reduce side effects.

People with blood cancers and those on chemotherapy may not respond adequately to their first two vaccine doses.

Improved detection methods could make a world of difference for patients undergoing cancer therapy.

A study from the Leukemia & Lymphoma Society finds that antibody production varies widely across blood cancer types.

Zynlonta led to complete remission in nearly a quarter of patients with large B-cell lymphoma.

After a median follow-up of 13 months, four of the five patients had ongoing complete remission.

After approval of the latest cellular therapy for non-Hodgkin lymphoma, the big challenge is how to extend it to common solid tumors.

Half of patients treated with Breyanzi experienced complete remission, and a majority of these responses were durable.

A former labor and delivery nurse, Lindy Sledge, 62, lives with her family in Franklin, Kentucky. She has mantle cell lymphoma.

Yescarta led to complete remission in people with advanced non-Hodgkin lymphoma.

A dedicated student of jiujitsu, Avie Barron, 36, was diagnosed with non-Hodgkin lymphoma in her right lung.

More than a third of people treated with Monjuvi plus Revlimid experienced complete remission.